Skip to main content
. 2020 Feb 14;9:1551. doi: 10.3389/fonc.2019.01551

Table 3.

Subgroup analyses of radiotherapy effect on BCSS in patients with different features.

Variable PMRT group death/patient No-PMRT group death/patient HR (95% CI) P
Age
   <40 128/1,315 141/1,195 1.03 (0.77–1.39) 0.831
   40–70 339/6,360 338/6,076 0.91 (0.76–1.10) 0.338
   ≥70 390/987 385/1,038 1.24 (1.04–1.48) 0.017
Race
   White 1,045/9,782 1,158/9,803 1.00 (0.92–1.08) 0.937
   Black 211/1,483 242/1,443 0.98 (0.82–1.18) 0.858
   Other 119/1,320 142/1,339 0.92 (0.72–1.17) 0.485
Marital status
   Married 818/8,187 961/8,193 0.94 (0.86–1.04) 0.223
   Unmarried 557/4,398 581/4,392 1.05 (0.93–1.18) 0.423
Tumor stage
   T1 297/4,188 366/4,176 0.96 (0.82–1.12) 0.607
   T2 1,078/8,397 1,176/8,409 0.99 (0.92–1.08) 0.911
Grade
   1 44/1,151 51/1,149 0.99 (0.66–1.50) 0.981
   2 384/5,261 487/5,242 0.99 (0.78–1.02) 0.105
   3 947/6,173 1,004/6,194 1.03 (0.94–1.12) 0.536
ER status
   Negative 560/2,854 602/2,806 0.96 (0.86–1.08) 0.482
   Positive 815/9,731 940/9,779 1.01 (0.92–1.11) 0.779
PR status
   Negative 733/4,218 785/4,191 0.99 (0.90–1.10) 0.914
   Positive 642/8,367 757/8,394 0.98 (0.88–1.09) 0.725
No. of LNs positive
   1 559/5,590 539/5,545 1.21 (1.08–1.36) 0.002
   2 418/3,923 538/4,276 0.96 (0.85–1.09) 0.552
   3 398/3,072 465/2,764 0.78 (0.64–0.90) <0.001
Chemotherapy
   No 168/1,591 187/1,592 1.01 (0.82–1.24) 0.955
   Yes 1,207/10,994 1,355/10,993 0.98 (0.91–1.06) 0.617